search
Back to results

REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children

Primary Purpose

Diphtheria, Tetanus, Poliomyelitis

Status
Completed
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
REVAXIS®
DT-Polio®
Sponsored by
Sanofi Pasteur, a Sanofi Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Diphtheria focused on measuring Prevention of : Diphtheria, Tetanus and Poliomyelitis

Eligibility Criteria

6 Years - 6 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy child without chronic severe disease of either gender,
  2. 6 year-old child on vaccination day,
  3. Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life and a booster dose of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination at 16 - 18 months of life (±2 months),
  4. Consent form signed by both parents, or by the legal representative, properly informed about the study.

Exclusion Criteria:

  1. Child who had received less or more than 4 doses of a diphtheria, tetanus and/or poliomyelitis containing vaccine,
  2. Previous clinical or bacteriological diagnosis of diphtheria, tetanus or poliomyelitis,
  3. Child who had received any vaccine in the previous 30 days or with a vaccination scheduled during the course of the study,
  4. Child who present with immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,
  5. Child who had received within the previous 150 days or who will receive during the course of the study, any immunoglobulins or blood derived products,
  6. Child with true hypersensitivity to at least one of the components of a study vaccine or to streptomycin, neomycin or polymixin B,
  7. Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,
  8. Child who had presented severe hypersensitivity following an earlier immunization against diphtheria and/or tetanus,
  9. Known history of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection,
  10. Acute severe febrile illness and/or oral temperature ≥37.5°C at the time of vaccination

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
March 12, 2007
Last Updated
September 8, 2017
Sponsor
Sanofi Pasteur, a Sanofi Company
search

1. Study Identification

Unique Protocol Identification Number
NCT00447525
Brief Title
REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children
Official Title
Comparison of the Immunogenicity and Safety of a Combined Adsorbed Low Dose Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (REVAXIS®) With a Combined Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (DT Polio®) When Given as a Booster Dose at 6 Years of Age
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
February 2007 (Actual)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi Pasteur, a Sanofi Company

4. Oversight

5. Study Description

Brief Summary
Primary objective: To demonstrate the non inferiority between REVAXIS® and DT Polio® when given as a second booster to healthy 6 year-old children . Secondary objectives: Additional immunogenicity assessments. To describe the safety profile of a single dose of REVAXIS® or DT-Polio®

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diphtheria, Tetanus, Poliomyelitis
Keywords
Prevention of : Diphtheria, Tetanus and Poliomyelitis

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
760 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
REVAXIS®
Intervention Type
Biological
Intervention Name(s)
DT-Polio®

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy child without chronic severe disease of either gender, 6 year-old child on vaccination day, Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life and a booster dose of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination at 16 - 18 months of life (±2 months), Consent form signed by both parents, or by the legal representative, properly informed about the study. Exclusion Criteria: Child who had received less or more than 4 doses of a diphtheria, tetanus and/or poliomyelitis containing vaccine, Previous clinical or bacteriological diagnosis of diphtheria, tetanus or poliomyelitis, Child who had received any vaccine in the previous 30 days or with a vaccination scheduled during the course of the study, Child who present with immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity, Child who had received within the previous 150 days or who will receive during the course of the study, any immunoglobulins or blood derived products, Child with true hypersensitivity to at least one of the components of a study vaccine or to streptomycin, neomycin or polymixin B, Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition, Child who had presented severe hypersensitivity following an earlier immunization against diphtheria and/or tetanus, Known history of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection, Acute severe febrile illness and/or oral temperature ≥37.5°C at the time of vaccination
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Sanofi Pasteur, a Sanofi Company
Official's Role
Study Director
Facility Information:
City
Albertville
ZIP/Postal Code
95880
Country
France
City
Albi
ZIP/Postal Code
81000
Country
France
City
Angers
ZIP/Postal Code
49100
Country
France
City
Annecy
ZIP/Postal Code
74000
Country
France
City
Anzin
ZIP/Postal Code
59410
Country
France
City
Arras
ZIP/Postal Code
62000
Country
France
City
Asnieres
ZIP/Postal Code
92600
Country
France
City
Avion
ZIP/Postal Code
62210
Country
France
City
Bassens
ZIP/Postal Code
33530
Country
France
City
Bersee
ZIP/Postal Code
59235
Country
France
City
Besancon
ZIP/Postal Code
25000
Country
France
City
Blois
ZIP/Postal Code
41000
Country
France
City
Boulogne
ZIP/Postal Code
92100
Country
France
City
Brest
ZIP/Postal Code
29200
Country
France
City
Broglie
ZIP/Postal Code
27270
Country
France
City
Caen
ZIP/Postal Code
14000
Country
France
City
Chalon-en-champagne
ZIP/Postal Code
51000
Country
France
City
Champdeniers
ZIP/Postal Code
79220
Country
France
City
Chigny Les Roses
ZIP/Postal Code
51500
Country
France
City
Cholet
ZIP/Postal Code
49300
Country
France
City
Claix
ZIP/Postal Code
38640
Country
France
City
Clamart
ZIP/Postal Code
92141
Country
France
City
Collombey Les Belles
ZIP/Postal Code
54170
Country
France
City
Draguignan
ZIP/Postal Code
83300
Country
France
City
Enghien-les-bains
ZIP/Postal Code
95880
Country
France
City
Floirac
ZIP/Postal Code
33270
Country
France
City
Frouard
ZIP/Postal Code
54390
Country
France
City
Haguenau
ZIP/Postal Code
67500
Country
France
City
Illkirch-graffenstaden
ZIP/Postal Code
67400
Country
France
City
Issy Les Moulineaux
ZIP/Postal Code
92130
Country
France
City
La Neuville Roy
ZIP/Postal Code
60190
Country
France
City
Laon
ZIP/Postal Code
02000
Country
France
City
Le Havre
ZIP/Postal Code
76600
Country
France
City
Les Pieux
ZIP/Postal Code
50340
Country
France
City
Louverne
ZIP/Postal Code
53950
Country
France
City
Louvigne de Bais
ZIP/Postal Code
35680
Country
France
City
Manduel
ZIP/Postal Code
30129
Country
France
City
Marcq-en-barouel
ZIP/Postal Code
59700
Country
France
City
Maromme
ZIP/Postal Code
76150
Country
France
City
Marseille
ZIP/Postal Code
13004
Country
France
City
Miniac Morvan
ZIP/Postal Code
35540
Country
France
City
Montpellier
ZIP/Postal Code
34080
Country
France
City
Montsang/orge
ZIP/Postal Code
91390
Country
France
City
Morangis
ZIP/Postal Code
91420
Country
France
City
Nancy
ZIP/Postal Code
54000
Country
France
City
Nantes
ZIP/Postal Code
44300
Country
France
City
Nogent Sur Marne
ZIP/Postal Code
94130
Country
France
City
Ostwald
ZIP/Postal Code
67540
Country
France
City
Paris
ZIP/Postal Code
75013
Country
France
City
Paris
ZIP/Postal Code
75019
Country
France
City
Plouzane
ZIP/Postal Code
29280
Country
France
City
Poitiers
ZIP/Postal Code
86000
Country
France
City
Pont A Mousson
ZIP/Postal Code
54700
Country
France
City
Quimper
ZIP/Postal Code
29000
Country
France
City
Rouen
ZIP/Postal Code
76000
Country
France
City
Rouen
ZIP/Postal Code
76100
Country
France
City
Saint Sebastien Sur Loir
ZIP/Postal Code
44230
Country
France
City
Saint-ouen
ZIP/Postal Code
93400
Country
France
City
Saint-raphael
ZIP/Postal Code
83700
Country
France
City
Sanary Mer
ZIP/Postal Code
83110
Country
France
City
Sevres
ZIP/Postal Code
92310
Country
France
City
Strasbourg
ZIP/Postal Code
67000
Country
France
City
Toulouse
ZIP/Postal Code
31000
Country
France
City
Villemomble
ZIP/Postal Code
93250
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
21441781
Citation
Gajdos V, Soubeyrand B, Vidor E, Richard P, Boyer J, Sadorge C, Fiquet A. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS ((R))) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio ((R))) given as a booster dose at 6 years of age. Hum Vaccin. 2011 May;7(5):549-56. doi: 10.4161/hv.7.5.14982. Epub 2011 May 1.
Results Reference
derived

Learn more about this trial

REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children

We'll reach out to this number within 24 hrs